/
Neurology
Peripheral Neuropathy
37
Pipeline Programs↗
70
Active Trials↗
43
Companies Involved↗
Peripheral Neuropathy is a moderately active landscape with 37 programs across 43 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Tarian Pharma, Vertex Pharmaceuticals. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 211
Phase 310
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
34 of 35 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 95% of 37 pipeline programs.
Analysis
Trial Status
255
clinical trials
Completed119 · 47%
Recruiting36 · 14%
Unknown status36 · 14%
Terminated23 · 9%
Not yet recruiting20 · 8%
Active, not recruiting13 · 5%
Other8 · 3%
Clinical Trials
Trial Activity
255 trials
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)